2018 International Congress » Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment

Date: Saturday, October 6, 2018

Time: 1:45pm-3:15pm

Location: Hall 3FG

Meeting: 2018 International Congress

1:45pm-3:15pm: ‘PDSAFE’ – A multi-dimensional fall rehabilitation intervention for people with Parkinson’s with specialist physiotherapy training: qualitative exploration of physio’s experiences

K. Seymour, S. Hulbert, V. Goodwin, L. Rochester, A. Nieuwboer, A. Ashburn (Southampton, United Kingdom)

1:45pm-3:15pm: 7 years later, are the Tomlinson’s levodopa dose equivalencies proposed consensual?

E. Dellapina, F. Ory-Magne, A. Sommet, V. Rousseau, D. Devos, S. Thobois, L. Defebvre, C. Brefel-Courbon, JC. Corvol, O. Rascol, F. NS-PARK/FCRIN Network (Toulouse, France)

1:45pm-3:15pm: A clinical tool to ensure delivery of modern personalised medicine for Parkinson’s disease: first description of a personalised medicine checklist

N. Titova, K. Ray Chaudhuri (Moscow, Russian Federation)

1:45pm-3:15pm: A Computer-Aided Prescription Model for Parkinson’s Disease could predict the suitable drugs for Parkinson’s disease (PD) patients

Y. Pan, L. Zhang (Nanjing, China)

1:45pm-3:15pm: A controlled trial of ParkinSong singing groups to improve communication and wellbeing in Parkinson’s disease

J. Tamplin, A. Vogel, C. Marigliani, F. Baker, M. Morris (Southbank, Australia)

1:45pm-3:15pm: A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Phase IIa Trial to Evaluate the Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson’s Disease

JC. Corvol, F. Durif, W. Meissner, JP. Azulay, R. Haddad, D. Bricout, X. Wang-Zhang, L. Benel, O. Rascol, Fr. NS-Park/F-CRIN Network (Paris, France)

1:45pm-3:15pm: A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease

H. Huttunen, S. Booms, J. Koskinen, M. Saarma (Espoo, Finland)

1:45pm-3:15pm: A multimodal motor skill balance training with rhythmical cues to improve and maintain balance control in Parkinson’s disease

T. Capato, J. Nonnekes, J. Tornai, I. Kayo, J. IntHout, E. Barbosa, N. de Vries, M. Piemonte, B. Bloem (Sāo Paulo, Brazil)

1:45pm-3:15pm: A novel mGlu4 PAM alleviates motor symptoms in primate models of PD and of LID

D. Charvin, T. Di Paolo, E. Bezard, L. Gregoire, A. Takano, G. Duvey, E. Pioli, C. Halldin, R. Medori, F. Conquet (Plan-les-Ouates, Switzerland)

1:45pm-3:15pm: A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone

S. Janhunen, J. Venäläinen, J. Kaskinoro, L. Saloranta, J. Tuunainen (Turku, Finland)

1:45pm-3:15pm: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson’s disease: Study Design

T. Simuni, B. Fiske, K. Merchant, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, C. Venuto, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff (Chicago, IL, USA)

1:45pm-3:15pm: A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson disease(STEADY-PD III): Baseline characteristics and study update

R. Holloway, D. Oakes, T. Simuni, K. Hodgeman, B. Greco, S. Henderson, J. Lowell, S. Sharma, C. Tarolli, K. Biglan (Rochester, NY, USA)

1:45pm-3:15pm: A phase Ib trial studying the safety and tolerability of IRL790 in patients with Parkinson’s disease and levodopa-induced dyskinesia

P. Svenningsson, A. Johansson, D. Nyholm, P. Tsitsi, C. Sonesson, J. Tedroff (Stockholm, Sweden)

1:45pm-3:15pm: A Physiotherapy Exercise Program for Parkinson’s Disease Patients with Impaired Gait and Postural Control

J. Yeung, A. Lau, E. Chan, J. Chung, L. Chan (Hong Kong)

1:45pm-3:15pm: A randomized double-blind placebo-controlled trial of probiotics for constipation in Parkinson’s disease

K.K. Chong, S.Y. Lim, M.A.A. A Manap, J.L. Lim, S.C. Low, S. K Mahadeva, A.H. Tan (Kuala Lumpur, Malaysia)

1:45pm-3:15pm: A single center retrospective analysis of Opicapone treatment in 90 Parkinson patients

M. Winterholler, H. Erxleben (Schwarzenbruck, Germany)

1:45pm-3:15pm: A Study to Evaluate the Efficacy of PRX002/RG7935 in Participants With Early Parkinson’s Disease (PASADENA) – Study Design

B. Mollenhauer, F. Boess, K. Marek, W. Poewe, R. Postuma, K. Taylor, J. Dukart, M. Lindemann, L. Verselis, M. Niggli, T. Barata, A. Post, M. Koller, D. Ness, D. Selkoe, J. Sevigny (Göttingen, Germany)

1:45pm-3:15pm: A Virtual Reality Exercise Program Improves the Balance Function and Quality of Life of Patients with Parkinson’s Disease

G. Lee (Cheonan, Republic of Korea)

1:45pm-3:15pm: Absence of wearing-off in Parkinson’s disease patients with treatment beyond 10 years

Q. Wei, R. Ou, Y. Wu, X. Yuan, Y. Hou, H. Liu, L. Zhang, Y. Chen, B. Cao, X. Chen, H. Shang (Chengdu, China)

1:45pm-3:15pm: Activities of Daily Living and Quality of Life in Patients with Advanced Parkinson’s Disease Who Are Treated with or Planning to Use Device-Aided Treatments

A. Fasano, K. Seppi, V. Fung, Z. Pirtosek, J.C. Parra, L. Bergmann, O. Sanchez-Soliño, B. Elibol, K. Onuk (Toronto, ON, Canada)

1:45pm-3:15pm: Acute efficacy and tolerability of the COMT inhibitor opicapone

F. Gandor, D. Sykora, D. Gruber, G. Ebersbach (Beelitz-Heilstätten, Germany)

1:45pm-3:15pm: After Deep Brain Stimulation Surgery for Parkinson’s Disease risk Factors for Postoperative Delirium

F. Rakhimov, G. Rakhimbaeva (Tashkent, Uzbekistan)

1:45pm-3:15pm: Ambulosono – A Music Walking Program Improves Gait Disorders in Parkinson’s Disease

W. Xian, B. Hu, T. Wu, L. Jiang, L. Chen, Z. Pei (Guangzhou, China)

1:45pm-3:15pm: Association analysis of the nutritional status and serum nutritional index in patients with Parkinson’s disease

L. Chen, W. Chen, Q. Guo, L. Jiang, Y. Hu, Y. Liu, W. Xian (Guangzhou, China)

1:45pm-3:15pm: Augmented Reality-Based Dance Application on Balance and Mobility of Individuals with Parkinson’s Disease: A Pilot Study

T. Tunur, K. Rickford, A. DeBlois, E. Horton-Yates, L. Columna (San Marcos, CA, USA)

1:45pm-3:15pm: Bdnf rs6265 and Other Variants Predict the Efficacy of Levodopa Monotherapy in Early-Stage Parkinson’s Disease

C. Sortwell, P. Auinger, J. Goudreau, B. Pickut, M. Hacker, P. Charles, J. Lipton, A. Cole-Strauss, J. Elm, D. Fischer (Grand Rapids, MI, USA)

1:45pm-3:15pm: Bio-Electro Stimulation Therapy for the Treatment of Motor and Non-Motor Symptoms in Parkinson’s Disease

T. Tsao, C. Fontana, A. Waite (Boston, MA, USA)

1:45pm-3:15pm: Botulinum toxin injection for Pisa syndrome in Parkinson’s disease

CA. Artusi, M. Zibetti, P. Barbero, M. Busso, S. Bortolani, S. De Mercanti, P. Arnoffi, M. Fabbri, A. Merola, L. Lopiano (Torino, Italy)

1:45pm-3:15pm: Can blood biomarkers differentiate Idiopathic Parkinson’s disease from Parkinson plus syndromes? A study from North Indian population

R. Shree, M. Mulagala, M. Modi, S. Mehta, M. Goyal, B. Medhi, V. Lal, B. Mittal (Chandigarh, India)

1:45pm-3:15pm: Can choice of games influence the therapeutic results obtained by training in virtual reality for gait improvement in people with Parkinson’s disease?

P. Barbosa, A. da Costa, A. Falconi, M. d'Alencar, M E. Piemonte (São Paulo, Brazil)

1:45pm-3:15pm: Challenging mitochondria in idiopathic Parkinson‘s disease fibroblasts

P. Antony, O. Boyd, K. Mommaerts, K. Sokolowska, M. Ostaszewski, A. Baumuratov, L. Longhino, F. Poulain, R. Krueger, R. Balling, N. Diederich (Belvaux, Luxembourg)

1:45pm-3:15pm: Characteristics of dopaminergic treatments in advanced Parkinson’s before levodopa-carbidopa intestinal gel infusion: Data from 107 tested patients

J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, D. Georgescu, J. Szederjesi, I. Mihaly, S. Szatmari (Tirgu Mures, Romania)

1:45pm-3:15pm: Classifying Parkinsonian Gait and Turning in Daily Life with Wearable Technology

F. Horak, J. McNames, M. El Gohary, J. Nutt, C. Curtze (Portland, OR, USA)

1:45pm-3:15pm: Clinical characteristics of turkish patients with Parkinson’s disease: A retrospective analysis of 428 patients

B. Gonenli Kocer, E. Ozturk, S. Comoglu (Ankara, Turkey)

1:45pm-3:15pm: Clinical characterization of Pramipexole induced edema and skin reaction in Parkinson’s Disease (PD) after one year of follow up

E. Urrea-Mendoza, N. Rincon, F. Revilla (Greenville, SC, USA)

1:45pm-3:15pm: Clinical effectiveness of a highly challenging balance training (HiBalance program) for Parkinson’s disease: A multi-center clinical effectiveness trial

B. Leavy, C. Joseph, N. Löfgren, H. Johansson, M. Hagströmer, E. Franzén (Stockholm, Sweden)

1:45pm-3:15pm: Clinical trial protocol: Restitution of oral transport, penetration and aspiration with nigral stimulation in Parkinson’s disease?

A. Schoellmann, L. Stoll, B. Hobl, C. Meisner, A. Gharabaghi, D. (Tuebingen, Germany)

1:45pm-3:15pm: Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation (CLOVER-DBS)

F. Sasaki, G. Oyama, S. Sekimoto, R. Nakamura, T. Jo, H. Iwamuro, A. Umemura, Y. Shimo, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: CLOVER-DBS: A Prospective, Multi-center Clinical Study with Blinding to Evaluate a Closed Loop Programming Algorithm for Directional Leads Based on External Feedback

A. Kuehn, G. Wenzel, C. Bruecke, L. Juarez Paz, K. Wynants, H. Scholtes, D. Blum (Berlin, Germany)

1:45pm-3:15pm: Combination Therapy of Ellagic Acid and Mucuna Pruriens Seeds Extract Improves Rotenone Induced Behavioural, Oxidative and Mitochondrial Deficits in Mice Model of Parkinson’s Disease

D. Khatri (Pune, India)

1:45pm-3:15pm: Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease

A. Pinna, G. Costa, M. Serra, M. Morelli (Monserrato (CA), Italy)

1:45pm-3:15pm: Combined catechol-O-methyl-transferase inhibition and intrajejunal Levodopa infusion: A real-life single-centre experience

R.N. Taddei, V. Leta, A. Sauerbier, M. Parry, A. Podlewska, L. Hall, S. Tentis, P. Odin, W. Poewe, P. Dubois, D. van Warmelen, E.W. Lim, K.R. Chaudhuri (London, United Kingdom)

1:45pm-3:15pm: Comparison of low versus high frequency stimulation on stuttering in Parkinson’s disease patients with bilateral subthalamic nucleus deep brain stimulation

O. Jitkritsadakul, K. Boonpang, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Compensation strategies for gait impairments in Parkinson’s disease

J. Nonnekes, E. Růžička, A. Nieuwboer, M. Hallett, A. Fasano, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: Contribution of ATP-sensitive potassium channels in the subthalamic nucleus neurons towards Parkinson’s disease

C. Mahapatra, R. Manchanda (Mumbai, India)

1:45pm-3:15pm: Correlation between severity of disease, spatio-temporal variables, and kinematic variables during forward and backward walking

M. Son, C. Youm, M. Lee, H. Park (Busan, Republic of Korea)

1:45pm-3:15pm: Delayed-onset Edema Surrounding Deep Brain Stimulation Leads: Insights From A Case Series and Literature Review

Y. Hu (Guangzhou, China)

1:45pm-3:15pm: Design of a Pharmacokinetics Study with Multiple Doses of Accordion Pill™ Carbidopa/Levodopa in Patients with Parkinson’s disease

C. Olanow, K. Kieburtz, J. Dubow, F. Stocchi, J. Meckler, N. Navon, R. Gendreau (Sarasota, FL, USA)

1:45pm-3:15pm: Design of a Phase 3 Efficacy and Safety Trial of Accordion Pill™ Carbidopa/Levodopa for Parkinson’s Disease (PD) Patients Experiencing Motor Fluctuations

P. LeWitt, R. Gendreau, J. Meckler, N. Navon (West Bloomfield, MI, USA)

1:45pm-3:15pm: Determinants of absence of dyskinesia in Parkinson’s disease patients with treatment beyond 10 years

R. Ou, Y. Wu, Q. Wei, X. Yuan, Y. Hou, H. Liu, L. Zhang, Y. Chen, B. Cao, X. Chen, H. Shang (Chengdu, China)

1:45pm-3:15pm: Development of a biomarker for Parkinson’s disease by measuring alpha-synuclein oligomers in cerebrospinal fluid with ultrasonication-induced amyloid fibril formation

K. Kakuda, K. Ikenaka, K. Araki, Y. Kajiyama, M. So, H. Hayakawa, T. Omichi, K. Baba, K. Konaka, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

1:45pm-3:15pm: Development of anti-amyloid drugs for Parkinson’s disease by combination screening of high-throughput in vitro assay and phenotype-based C. elegans system

K. Ikenaka, K. Araki, S. Sonoda, T. Takeuchi, Y. Nagai, Y. Goto, H. Mochizuki (Suita, Japan)

1:45pm-3:15pm: DIRECT DBS: A Prospective, Multicenter Clinical Study with Double-Blinding for a Directional Deep Brain Stimulation Lead – Intra-visit Impedance Changes

F. Steigerwald, J. Volkmann, C. Matthies, A. Dalal Kirsch, S. Chabardes, R. de Bie, PR. Schuurman, E. Moro, V. Fraix, S. Meoni, D. Blum, L. Juarez Paz, K. Wynants, N. Van Dyck (Würzburg, Germany)

1:45pm-3:15pm: DIRECT DBS: A Prospective, Multicenter Clinical Study with Double-Blinding for a Directional Deep Brain Stimulation Lead – Visualization of Optimal Directionally Stimulated Anatomy

F. Steigerwald, J. Volkmann, C. Matthies, A. Dalal Kirsch, S. Chabardes, R. de Bie, PR. Schuurman, E. Moro, V. Fraix, S. Meoni, D. Blum, L. Juarez Paz, K. Wynants, N. Van Dyck (Würzburg, Germany)

1:45pm-3:15pm: DIRECT DBS: A Prospective, Multicenter Clinical Study with Double-Blinding for a Directional Deep Brain Stimulation Lead – Therapeutic Windows with Directional Stimulation

F. Steigerwald, J. Volkmann, C. Matthies, A. Dalal Kirsch, S. Chabardes, R. de Bie, P. Schuurman, E. Moro, V. Fraix, S. Meoni, D. Blum, L. Juarez Paz, K. Wynants, N. Van Dyck (Würzburg, Germany)

1:45pm-3:15pm: Directional Deep Brain Stimulation: First experiences in centers across the globe

T. ten Brinke, V. Odekerken, J. Dijk, P. vd Munckhof, P. Schuurman, R. de Bie (Amsterdam-Zuidoost, Netherlands)

1:45pm-3:15pm: Directional Lead Impedances and Their Possible Effects on Deep Brain Stimulation

L. Juarez Paz, A. Dalal Kirsch, F. Steigerwald, C. Matthies, S. Meoni, V. Fraix, T. Ten Brinke, R. de Bie, K. Wynants, D. Blum, N. Van Dyck, PR. Schuurman, E. Moro, S. Chabardes, J. Volkmann (Valencia, CA, USA)

1:45pm-3:15pm: Does altering medication to avoid dyskinesia positively alters the breadth of the motor repertoire of patients with Parkinson’s disease? A pilot study

S. Bogard, E. Goubault, K. Lebel, C. Duval (Montreal, QC, Canada)

1:45pm-3:15pm: Does motor laterality affect the development of dyskinesia in patients with Parkinson’s disease?

S. Chung, H. Yoo, J. Oh, J. Kim, P. Lee, Y. Sohn (Seoul, Republic of Korea)

1:45pm-3:15pm: Does the effect of continuous levodopa infusion treatment for Parkinson’s disease regress as the day progresses?

I. Thomas, M. Memedi, D. Nyholm, J. Westin (Borlange, Sweden)

1:45pm-3:15pm: Double-blind controlled trial of Spectramax™ light therapy for the treatment of Parkinson’s disease patients on stable dopaminergic therapy

A. Videnovic, S. Rutten, W. Croft, H. Erickson, J. Groves, C. Havemann, T. Herrington, S. Hendrix, K. Kieburtz, Y. vander Werf, O. vanden Heuvel (Boston, MA, USA)

1:45pm-3:15pm: Dual device aided therapy for patients with advanced Parkinson’s Disease: A case series

A. Faust- Socher, G. Yahalom, M. Kestenbaum, A. Hilel, S. Israeli-Korn, A. Thaler, H. Strauss, H. Shabtai, S. Hassin-Baer, N. Giladi, T. Gurevich, O. Cohen (Tel Aviv, Israel)

1:45pm-3:15pm: Dual task in the daily life of patients with Parkinson’s disease

K. Mejia (Lima, Peru)

1:45pm-3:15pm: Dyskinesia management in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience

J. Pagonabarraga, E. Tolosa, J. Ferreira, A. Lees, E. Arbe, J. Rocha, P. Soares-da-Silva (Barcelona, Spain)

1:45pm-3:15pm: Dysphagia predicts poor outcome in late-stage Parkinson’s disease

M. Fabbri, D. Abreu, L. Guedes, M. Rosa, A. Antonini, M. Zibetti, L. Lopiano, J. Fereira, M. Coelho (Lisbon, Portugal)

1:45pm-3:15pm: Effect of Ba Duan Jin Exercise on Non-Motor Symptoms, Motor Symptoms, Gait and Balance in Patients with Mild to Moderate Parkinson’s Disease

Z. Cai, S. Dong (Lianyungang City, China)

1:45pm-3:15pm: Effect of COMT-inhibitor in the clinical progression of Parkinson’s disease

I.U. Song, K.S. Lee, Y.A. chung (Incheon, Republic of Korea)

1:45pm-3:15pm: Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease

J. Chen, J. Hong, L. Chunfeng (Suzhou, China)

1:45pm-3:15pm: Effect of dual task as rehabilitation therapy in Parkinson’s disease in the UPDRS III

C. Mejia (Lima, Peru)

1:45pm-3:15pm: Effect of exercise on neurodegenerative parkinsonism unmasked by dopamine blocking drugs (DRBD)

J. Morley, S. Wood, G. Cheng, K. Browne, K. Robinson, D. Weintraub, J. Duda (Philadelphia, PA, USA)

1:45pm-3:15pm: Effect of finger rhythmic movement training on freezing of gait in Parkinson’s disease patients: A study protocol

H. Nakano, S. Murata, T. Kodama, H. Nakae, M. Soma (Kyoto-city, Japan)

1:45pm-3:15pm: Effect of lidocaine injection into the external oblique muscle on camptocormia and the lateral slant posture in patient with Parkinson’s disease

Y. Higashi, M. Tabata, T. Tabuchi, Y. Hattori (Himeji, Japan)

1:45pm-3:15pm: Effect of mindfulness yoga on psychological distress in people with Parkinson’s disease (PD): A randomized controlled trial

J.Y.Y. Kwok, J.C.Y. Kwan, M. Auyeung, C.T. Mok, C.K.Y. Lau, H.Y.L. Chan (New Territories, Hong Kong)

1:45pm-3:15pm: Effective physiotherapy program for Parkinson’s disease

I. Toyoshima, K. Hasegawa, M. Doi (Yurihonjo, Japan)

1:45pm-3:15pm: Effectiveness and safety of acupuncture in the treatment of Parkinson’s disease: A systematic review and meta-analysis of randomized controlled trials

CN. Ko, SU. Park, SY. Cho, JM. Park (Seoul, Korea)

1:45pm-3:15pm: Effectiveness of a Multi-disciplinary Parkinson’s Disease (PD) Clinic: A 2-year Prospective Observational Study

G. Chan, N. Cheung, S. Or, I. Chan, A. Leung, C. Li, D. Chau, C.W. Woo, B. Chee, W.C. Fong (Hong Kong)

1:45pm-3:15pm: Effectiveness of Rotigotine plus Intensive and Goal-based Rehabilitation versus Rotigotine alone in “de-novo” Parkinsonian subjects: A Randomized Controlled Trial with 18-month Follow-up

D. Ferrazzoli, P. Ortelli, G. Riboldazzi, R. Maestri, G. Frazzitta (Gravedona ed Uniti, Italy)

1:45pm-3:15pm: Effects of Expiratory Muscle Strength Training and Voice Therapy on Parkinsonian Speech

T.S. Tong, M.W. Ng (Pokfulam, Hong Kong)

1:45pm-3:15pm: Effects of High-frequency Repetitive Transcranial Magnetic Stimulation (HF-rTMS) Combined with Task Specific Training in Individuals with Parkinson’s Disease

J. Thanakamchokchai, J. Tretriluxana, B. Fisher, N. Pakaprot, A. PisarnPong (Nakhon Pathom, Thailand)

1:45pm-3:15pm: Effects of Intensive Voice and Articulation Treatments on Voice Quality in Parkinson’s disease

J. Spielman, L. Ramig, K. Freeman, A. Halpern, Y. Maryn (Denver, CO, USA)

1:45pm-3:15pm: Effects of JN403, an α-7-nicotine-acetylcholine-receptor (α7-nAChR) agonist on human alpha-synuclein-mediated in vitro and in vivo models of Parkinson’s disease

B. Lee, C. Noelker, W. Chiu, D. Feuerbach, L. Timmerman, W. Oertel (Marburg, Germany)

1:45pm-3:15pm: Effects of Korean Medicine on Postural Instability and Gait Difficulty in Patient with Parkinsonism

HM. Lee, SB. Yang, SY. Cho, JM. Park, CN. Ko, SU. Park (Seoul, Republic of Korea)

1:45pm-3:15pm: Effects of non-invasive brain stimulation on motor-speech disorders in Parkinson’s disease

I. Rektorova, P. Klobusiakova, L. Brabenec, J. Mekyska, Z. Galaz, M. Kostalova (Brno, Czech Republic)

1:45pm-3:15pm: Effects of progressive resistance and flexibility exercise program of trunk on static and dynamic stability for Parkinson’s disease

M. Lee, C. Youm, M. Son, H. Park, Y. Kim (Busan, Republic of Korea)

1:45pm-3:15pm: Effects of Rock Steady Boxing on Activities of Daily Living and Motor Symptoms of Parkinson’s Disease

D. Larson, D. Bega, E. Johnson, L. Slowey (Chicago, IL, USA)

1:45pm-3:15pm: Effects of rTMS on three cortical areas in Parkinson’s Disease

V. Goyal, P. Bhat, C. Goyal, A. Srivastava, S. Kumaran, M. Behari, S. Dwivedi (Delhi, India)

1:45pm-3:15pm: Effects of the Lee Silverman Voice Treatment (LSVT LOUD ®) on Facial Expressivity in Individuals with Parkinson’s Disease (PD) as a function of Emotional Valence

A. Bono, K. Scorpio, R. Stafford, M. Halfacre, E. Murray, J. Twaite, K. Alterescu, J. Spielman, A. Halpern, L. Ramig, J. Borod (Flushing, NY, USA)

1:45pm-3:15pm: Efficacy and safety of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: A systematic review of randomized controlled trials

S. Hussain, A. Najmi (New Delhi, India)

1:45pm-3:15pm: Efficacy and security starting safinamide treatment with 100 mg/day in PD

N. Foncea (Galdakao, Spain)

1:45pm-3:15pm: Efficacy of combined treatment with acupunture and bee venom acupuncture for Parkinson’s disease: Double blind randomized controlled trial

S.U. Park, H.M. Lee, S.Y. Cho, J.M. Park, C.N. Ko (Seoul, Republic of Korea)

1:45pm-3:15pm: Efficacy of CVT-301 (levodopa inhalation powder) for treatment of OFF periods in Parkinson’s disease

R. Pahwa, I. Abeynayake, M. Klingler, A. Sedkov, C. Kenney, C. Oh (Overland Park, KS, USA)

1:45pm-3:15pm: Efficacy of ND0612 for nocturnal problems and early morning OFF

F. Stocchi, W. Poewe, T. Rachmilewitz Minei, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: NMSS analysis from the BIPARK-I double-blind experience

A. Antonini, J. Ferreira, W. Poewe, O. Rascol, H. Gama, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Padova, Italy)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Responder analyses from the BIPARK-I double-blind experience

J. Ferreira, A. Lees, W. Poewe, O. Rascol, A. Santos, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: The BIPARK-I double-blind experience

J. Kulisevsky, E. Tolosa, J. Ferreira, A. Lees, H. Gama, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Barcelona, Spain)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: UPDRS-II and III analysis from the BIPARK-I double-blind experience

G. Ebersbach, J. Ferreira, F. Stocchi, R. Costa, E. Arbe, J-F. Rocha, P. Soares-da- (Beelitz, Germany)

1:45pm-3:15pm: Efficacy of prolonged release melatonin for REM sleep behaviour disorder in Parkinson’s disease: A double blind, randomised, placebo-controlled trial

M. Gilat, R. Grunstein, N. Marshall, D. Hammond, A. Coeytaux Jackson, A. Mullins, J. Hall, S. (Sydney, Australia)

1:45pm-3:15pm: Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from the Phase 3 double-blind, placebo-controlled trial

S. Factor, S. Isaacson, K. Sciarappa, P. Bhargava, G. Vakili, A. Agro, D. Blum, W. Olanow, B. Navia (Atlanta, GA, USA)

1:45pm-3:15pm: Emulating the natural timing of dopamine receptor activation in Parkinson’s Disease

J. Reynolds, B. Hyland, J. Wickens, E. Tan (Dunedin, New Zealand)

1:45pm-3:15pm: Epidemiological and clinical profile of Parkinson’s disease in Douala

J. Doumbe, H. Bohongwe, Y. Mapoure, C. Kuate (Douala, Cameroon)

1:45pm-3:15pm: Evaluating long-term effectiveness of carbidopa/levodopa enteral suspension in advanced Parkinson’s Disease patients: PROviDE study design and baseline characteristics

R. Pahwa, R. Dorsey, P. Kandukuri, Y. Bao, J. Zamudio, I. Pan, Y. Jalundhwala (Kansas City, KS, USA)

1:45pm-3:15pm: Evaluation clinical-biochemical features of Parkinson’s disease

D. Daminov, G. Rakhmatullaeva (Tashkent, Uzbekistan)

1:45pm-3:15pm: Evaluation of the interaction between safinamide and opicapone in Parkinson’s disease patients with fluctuations

J. Garcia-Caldentey, MA. Prats-Sedano, I. Legarda-Ramirez, E. Estelrich-Peyret, B. Vives-Pastor, PJ. Garcia (Palma de Mallorca, Spain)

1:45pm-3:15pm: Exercise to improve upper limb function in people with Parkinson’s disease: A systematic review

E. Proud, J. Blennerhassett, J. Tan, K. Miller, M. Morris, J. McGinley (Parkville, Australia)

1:45pm-3:15pm: Exploring the utility of the ChulaPD intelligent Parkinson’s disease car to determine naturalistic driving ability in Parkinson’s disease patients: A pilot study of 10 patients

O. Jitkritsadakul, S. Krootjohn, P. Yanthitirat, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Final MDS-UPDRS, Part IV Results of the EASE LID 2 Study: Long Term, Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients

R. Hauser, R. Pahwa, C. Tanner, W. Oertel, R. Johnson, L. Felt, MJ. Stempien, R. Patni (Tampa, FL, USA)

1:45pm-3:15pm: Final Safety Results of EASE LID 2 Study: Long Term Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients

S. Isaacson, R. Pahwa, C. Tanner, R. Hauser, W. Oertel, R. Johnson, L. Felt, M.J. Stempien, R. Patni (Boca Raton, FL, USA)

1:45pm-3:15pm: Five Year Outcomes of a Prospective, Multicenter Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s Disease

L. Timmermann, R. Jain, N. Van Dyck, L. Chen, T. Brücke, F. Siejo, E. Suarez-San Martin, V. Visser-Vandewalle, M. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch (Köln, Germany)

1:45pm-3:15pm: Frequency-dependent effects of subthalamic deep brain stimulation on motor symptoms in Parkinson’s disease

D. Su, W. Hu, H. Chen, J. Zhou, T. Feng (Beijing, China)

1:45pm-3:15pm: Gait disorders in Parkinson’s disease: 19 observations at the University Hospital Center of Conakry

F. Sakadi, C. Abass, T. Rahamatou, B. Talibé, N. Woga, B. Kenda, C. Amara (Conakry, Guinea)

1:45pm-3:15pm: Gait speed after applying anodal-transcranial Direct Current Stimulation in people with Parkinson’s disease? Preliminary results

V. Alizad, M. Meinzer, L. Frossard, R. Polman, S. Smith, G. Kerr (Brisbane, Australia)

1:45pm-3:15pm: Gastric Retention of the Accordion Pill™: Results From MRI Studies With Parkinson’s Disease Patients and Healthy Volunteers

N. Navon, R. Gendreau, J. Meckler (Jerusalem, Israel)

1:45pm-3:15pm: GASTROPARK: Multicenter study on the efficacy of dopamine agonists for gastrointestinal symptoms in Parkinson’s disease

J. Martinez Castrillo, A. Alonso Canovas, G. Fernandez Pajarin, L. Vela Desojo, J. Garcia Caldentey, P. Sanchez Alonso, M. Fernandez Moreno, M. Mata, J. Herreros Rodriguez, J. Infante, J. Ruiz Martinez, C. Ruiz Huete, S. Fanjul Arbos, P. Garcia Ruiz (Madrid, Spain)

1:45pm-3:15pm: Highly-selective blockade of 5-HT2A receptors with EMD-281,014 reduces the severity of L-DOPA-induced psychosis and dyskinesia in the MPTP-lesioned marmoset model of Parkinson’s disease

A. Hamadjida, D. Bedard, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm: Home based exercises to reduce falls in people with Parkinson’s disease: A randomized trial

M. Morris, N. Taylor, J. McGinley, M. Danoudis, H. Menz (Bundoora, Australia)

1:45pm-3:15pm: Immediate Effect of Elastic Taping on Balance and Postural Control in Early Parkinson’s Disease: A Pilot Study

E. Göz, B. Balci, B. Dönmez, Çolakoğlu, R. Çakmur (Izmir, Turkey)

1:45pm-3:15pm: Impact of Age on Levodopa dosage regimes in Idiopathic Parkinson’s Disease

L. Scourfield, S. Sultana, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

1:45pm-3:15pm: Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials

R. Pahwa, S. Isaacson, J. Jimenez-Shahed, I. Malaty, A. Deik, R. Gandhy, R. Johnson, R. Patni (Kansas City, KS, USA)

1:45pm-3:15pm: Impact of SYN120 (a Dual 5-HT6/5-HT2A antagonist) on psychiatric symptoms in patients with Parkinson’s disease dementia: Results from a Phase 2a Study

D. Weintraub (Philadelphia, PA, USA)

1:45pm-3:15pm: Impact on the Quality of Life (CV) of people with Parkinson’s disease participating in community workshops of the public health system of Coquimbo, Chile

S. Stange, D. Mansilla, Y. Diaz, Y. Córdoba (Coquimbo, Chile)

1:45pm-3:15pm: Impulse control disorders could be accompanied by hypomanic state under intestinal levodopa infusion

K. Kashihara, M. Kitayama (Okayama, Japan)

1:45pm-3:15pm: Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry

D. Johansson, A. Ericsson, A. Johansson, A. Medvedev, D. Nyholm, F. Ohlsson, M. Senek, J. Spira, I. Thomas, J. Westin, F. Bergquist (Gothenburg, Sweden)

1:45pm-3:15pm: Influence of baseline OFF-time in the efficacy response of opicapone in Parkinson’s disease patients with motor fluctuations: The BIPARK-I double-blind experience

P. Korlipara, J. Ferreira, H. Gama, A. Santos, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

1:45pm-3:15pm: Inhibition of HDAC4 attenuates rotenone-induced abnormal increase of α-synuclein levels and affects autophagic flux in human dopaminergic SH-SY5Y cells

L. Wang, L. Liu, T. Wang (Wuhan, China)

1:45pm-3:15pm: Integrated Complimentary Yoga and Ayurveda Treatment Confers Significant Benefits in PD Patients

H. Babu, U. Kumbhare, T. Raju, N. R, N. R (Bengaluru, India)

1:45pm-3:15pm: Intranasal Delivery of Bromocriptine loaded Lipid Nano Carriers for Enhanced Brain Delivery in Parkinson’s disease

S. V G, P. Vavia (Mumbai, India)

1:45pm-3:15pm: Is there a relationship between depression/anxiety and physical inactivity in Parkinson Disease?

B. Aktar, B. Balci, B. Donmez Colakoglu (Izmir, Turkey)

1:45pm-3:15pm: It takes two to tango but following may be more beneficial for rehabilitating people with mild-moderate Parkinson’s

M. Hackney, A. Hart, C. Kim (Atlanta, GA, USA)

1:45pm-3:15pm: L-Dopa responsiveness in early Parkinson’s disease: Results from the United Kingdom Tracking Parkinson’s study

N. Malek, S. Kanavou, M. Lawton, K. Grosset, V. Pitz, N. Bajaj, R. Barker, D. Burn, T. Foltynie, J. Hardy, N. Wood, N. Williams, H. Morris, Y. Ben-Shlomo, D. Grosset (Ipswich, United Kingdom)

1:45pm-3:15pm: Level of serum Mortalin in Parkinson’s disease correlating with -Synuclein: Assessment of protein marker for early detection

S. Dey, A. Singh, T. Bajaj, A.B. Dey (New Delhi, India)

1:45pm-3:15pm: Levodopa Effect on Dual-Tasking in Freezing of Gait in Parkinson’s Disease

E. Bayram, J. Longhurst, S. Banks, Z. Mari, B. Bluett (Las Vegas, NV, USA)

1:45pm-3:15pm: Levodopa induced dyskinesia is preventable (15 years experience using continuous dopaminergic stimulation)

M. Lin, R. Laureno (Washington, DC, USA)

1:45pm-3:15pm: Levodopa Induced Orthostatic Hypotension in Parkinson’s Disease: A Single-Dose Response Study

K. Thiankhaw, S. Tanprawate, A. Soontornpun, A. Nudsasarn, S. Chankrachang (Chiang Mai, Thailand)

1:45pm-3:15pm: Liquid sinemet in the management of complex motor fluctuations in advanced Parkinson’s Disease

C. Sung, M. Danoudis, R. Iansek (Melbourne, Australia)

1:45pm-3:15pm: Long-Duration Response to Levodopa in advanced Parkinson’s Disease: Relevance for RCT on Disease-Modifying therapies

R. Cilia, E. Cereda, A. Akpalu, S. Sarfo, M. Cham, G. Pezzoli (Milan, Italy)

1:45pm-3:15pm: Long-term effect of subthalamic nucleus deep brain stimulation on freezing of gait in patients with advanced Parkinson’s disease

R. Kim, C.W. Shin, H. Park, A. Kim, H.J. Kim, S.H. Paek, B. Jeon (Seoul, Republic of Korea)

1:45pm-3:15pm: Longitudinal observational study on late onset Parkinson’s disease over a decade

S. Raha, L. Ebenezer (Bridgend, United Kingdom)

1:45pm-3:15pm: Magnetic resonance imaging-guided focused ultrasound unilateral pallidotomy for Parkinson’s disease: A report of 2 patients

H. Ito, T. Taira, S. Fukutake, K. Yamamoto, T. Yamaguchi, T. Kamei (Fujisawa, Japan)

1:45pm-3:15pm: Management of chronic polyneuropathy associated with levodopa-carbidopa intestinal gel infusion in Parkinson’s disease: Review of the strategies and perspectives

C. Cransac, J. Dupouy, P. Loubiere, B. Ackett, P. Cintas, C. Brefel Courbon, O. Rascol, F. ory Magne (Toulouse, France)

1:45pm-3:15pm: Mitochondrial morphometrics in idiopathic Parkinson‘s disease fibroblasts

P. Antony, O. Boyd, K. Mommaerts, K. Sokolowska, M. Ostaszewski, A. Baumuratov, L. Longhino, F. Poulain, R. Krueger, R. Balling, N. Diederich (Belvaux, Luxembourg)

1:45pm-3:15pm: Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)

B. Greco, R. Holloway, K. Hodgeman, S. Henderson, C. Tarolli, K. Biglan, T. Simuni (Rochester, NY, USA)

1:45pm-3:15pm: Neuromodulatory role of subthalamic nucleus deep brain stimulation in Parkinson’s disease patients

S. Szlufik, A. Przybyszewski, K. Duszynska-Was, I. Laskowska-Levy, J. Dutkiewicz, A. Drzewinska, P. Habela, T. Mandat, D. Koziorowski (Warsaw, Poland)

1:45pm-3:15pm: Neurorestorative effects of glycine transporter 1-inhibitor and D-Serine in a mouse model of nigrostriatal dopaminergic degeneration

V. Francardo, Y. Schmitz, D. Sulzer, M.A. Cenci (Lund, Sweden)

1:45pm-3:15pm: Novel COMT inhibitor opicapone shows sustained inhibition and improved L-DOPA availability in monkeys

T. Kitajima, M. Bonifácio, P. Moser, P. Soares-da-Silva, M. Tanaka (Osaka, Japan)

1:45pm-3:15pm: Novel mechanistic involved in targeting Parkinsons Disease by Indolocarbazole derivatives as inhibitors against Cyclin Dependent kinases using molecular modelling and simulation approaches

S. Iqbal (Chennai, India)

1:45pm-3:15pm: Objective analysis of walking tremor in Parkinson’s disease: A spectrum of classical rest tremor?

N. Dadphan, O. Jitkritsadakul, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Occurrence of dopaminergic adverse-events in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience

K. Chaudhuri, A. Sauerbier, J. Ferreira, F. Stocchi, E. Arbe, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

1:45pm-3:15pm: Occurrence of dopaminergic adverse-events in patients that switched from entacapone to opicapone: The BIPARK-I open-label experience

A. Ceballos-Baumann, K. Eggert, J. Ferreira, W. Poewe, O. Rascol, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Munich, Germany)

1:45pm-3:15pm: ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects

J. Tuunainen, J. Ellmén, M. Vahteristo, A. Holopainen, D. Strugala (Espoo, Finland)

1:45pm-3:15pm: On Converting Patients From Oral Dopamine Agonists to the Carbidopa/Levodopa Enteral Suspension Method – Real World Conversion Ratios

S. Nakano, L. Bahroo, F. Pagan, F. Amjad, S. Lo, I. Gambhir (Washington, D.C., DC, USA)

1:45pm-3:15pm: Ondansetron, a highly-selective 5-HT3 receptor antagonist, alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

C. Kwan, I. Frouni, D. Bédard, A. Hamadjida, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm: Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy

P. Howson, T. Johnston, J. Brotchie, M. Hill, J. Koprich (Toronto, ON, Canada)

1:45pm-3:15pm: Oral treatment with sphingosine-1-phosphate receptors modulator prevents Parkinson symptoms concomitantly to reduced brain inflammation in MPTP mouse models

M. Cyr, E. Pépin, G. Massicotte (Trois-Rivieres, QC, Canada)

1:45pm-3:15pm: Outcomes of a Prospective, Multi-center International Registry of Deep Brain Stimulation for Parkinson’s Disease

G. Deuschl, R. Jain, H. Scholtes, A. Wang, M. Barbe, S. Paschen, A. Andrea Kühn, M. Pötter-Nerger, J. Volkmann, J. Vesper (Kiel, Germany)

1:45pm-3:15pm: Patient and Provider Experiences and Attitudes toward Rytary

S. Horn, D. Coughlin, J. Chou, F. Wang, M. Stacy, R. Dolhun, C. Kopil, N. Amondikar, A. Deik, H. Sarva (Philadelphia, PA, USA)

1:45pm-3:15pm: Perceived Psychosocial Impacts of a Therapeutic Yoga Intervention for Individuals with Parkinson’s Disease (PD)

B. Hawkins, M. Van Puymbroeck, A. Walter, K. Woschkolup, E. Urrea-Mendoza, F. Revilla, A. Schmid (Clemson, SC, USA)

1:45pm-3:15pm: Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s disease during deep brain stimulation surgery: 2-year follow-up study of gait parameters

Z. Guduru, G. Gera, G. Quintero, C. Van Horne, G. Gerhardt (Lexington, KY, USA)

1:45pm-3:15pm: PLG restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models

J. Liu, H. Yang (Beijing, China)

1:45pm-3:15pm: Prevalence, Distribution and Management of Parkinson among Pakistani Population

S. Naureen (Rawalpindi, Pakistan)

1:45pm-3:15pm: PROtein, LEucine And vitamin D Enhancing Rehabilitation (PRO-LEADER) in patients with Parkinson’s disease or parkinsonism: A RCT

M. Barichella, E. Cereda, G. Pinelli, L. Iorio, D. Caroli, I. Masiero, V. Ferri, E. Cassani, C. Bolliri, S. Caronni, P. Ortelli, D. Ferrazzoli, A. Maras, G. Riboldazzi, G. Frazzitta, G. Pezzoli (Milano, Italy)

1:45pm-3:15pm: Putative treatment of Parkinson’s Disease using extract of Bacopa monnieri

S. Sinha, P. Kumar (Allahabad, India)

1:45pm-3:15pm: Quantifying the Reproducibility of an In Vivo Assay: Examination of Historical Amantadine Effects in the macaque Model of L-DOPA-Induced Dyskinesia

E. Pioli, P. Stanley, W. Ko, Q. Li, R. Kozak, P. Popiolek, E. Bezard (Manchester, United Kingdom)

1:45pm-3:15pm: Quantitative assessment of the effectiveness of adaptive Deep Brain Stimulation in Parkinson’s disease

D. Piña-Fuentes, M. Tijssen, M. Oterdoom, S. Little, J. van Zijl, T. van Laar, P. Brown, M. van Dijk, M. Beudel (Groningen, Netherlands)

1:45pm-3:15pm: Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study

K. Chaudhuri, D. Weintraub, A. Antonini, W. Robieson, M. Li, K. Chatamra, J. Benesh, M. Facheris (London, United Kingdom)

1:45pm-3:15pm: Real-World Outcomes Using a Novel Directional Lead from a Deep Brain Stimulation (DBS) Registry for Parkinson’s Disease

G. Deuschl, R. Jain, H. Scholtes, A. Wang, M. Barbe, A. Kühn, M. Pötter-Nerger, J. Volkmann, S. Paschen, J. Vesper (Kiel, Germany)

1:45pm-3:15pm: Relationship between Patient Global Impression of Change and other Efficacy Endpoints in Parkinson’s Disease: A post-hoc analysis from combined BIPARK-I and II

J. Ferreira, W. Poewe, O. Rascol, R. Costa, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

1:45pm-3:15pm: Remotely supervised home-based aerobic exercise for Parkinson patients

N. vd Kolk, N. de Vries, B. Post, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: Safety and Efficacy of Levodopa-Carbidopa Monotherapy in Patients with Advanced Parkinson’s Disease

J. Boyd, C. Zadikoff, M. Siddiqui, J. Benesh, J. Zamudio, W. Robieson, P. Kukreja (Burlington, VT, USA)

1:45pm-3:15pm: Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial

R. Pahwa, R. Hauser, M. Worden, P. Bhargava, G. Vakili, A. Agro, D. Blum, W. Olanow, B. Navia (Kansas City, KS, USA)

1:45pm-3:15pm: Safinamide add-on therapy increases ON time without dyskinesia in fluctuating Parkinson’s Disease (PD) patients with moderate to severe dyskinesia

V. Tubazio, C. Cattaneo, E. Bonizzoni, C. Keywood (Bresso (Milan), Italy)

1:45pm-3:15pm: Safinamide effect in patients with Parkinson’s disease and deep brain stimulation

F. Mancini, A. Di Fonzo, G. Lazzeri, L. Borellini, V. Silano, M. Lacerenza, C. Comi (Milan, Italy)

1:45pm-3:15pm: Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial

M. Schwarzschild, E. Macklin, R. Bakshi, S. Bhattacharyya,, R. Logan, A. Ascherio; on behalf of the Parkinson Study Group SURE-PD Investigators (Boston, MA, USA)

1:45pm-3:15pm: Speech Intelligibility in Parkinson’s disease following Intensive Voice and Articulation Treatments

G. Schulz, A. Halpern, J. Spielman, L. Ramig, I. Panzer, A. Sharpley, H. Hodges (Silver Spring, MD, USA)

1:45pm-3:15pm: STEEred vs RING-mode Deep Brain Stimulation for Parkinson’s disease: STEERING trial

T. ten Brinke, V. Odekerken, J. Dijk, P. vd Munckhof, P. Schuurman, R. de Bie (Amsterdam, Netherlands)

1:45pm-3:15pm: Study On Patient- And Caregiver-Reported Symptoms And Outcomes With Levodopa-Carbidopa Intestinal Gel For The Treatment Of Advanced Parkinson’s Disease. ADEQUA Study

F. Valldeoriola, M.J. Catalán, F. Escamilla-Sevilla, E. Freire, J. Olivares, E. Cubo, D. Santos, J.C. Parra, G. Arroyo, J.M. Arbelo (Barcelona, Spain)

1:45pm-3:15pm: SURE-PD3 Trial Participant Features prior to Randomization

E. Macklin, A. Videnovic, C. Lungu, C. Kamp, C. Casaceli, D. Oakes, A. Ascherio, M. Schwarzschild; on behalf of the Parkinson Study Group SURE-PD3_Investigators (Boston, MA, USA)

1:45pm-3:15pm: Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson

V. Kumar (Allahabad, India)

1:45pm-3:15pm: Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results of the 1-year extension BIPARK-I study

O. Fabregues, E. Tolosa, J. Ferreira, A. Lees, A. Santos, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Barcelona, Spain)

1:45pm-3:15pm: Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results of the 1-year extension BIPARK-I study

R. Ehret, J. Ferreira, F. Stocchi, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Berlin, Germany)

1:45pm-3:15pm: SYN120 (a Dual 5-HT6/5-HT2A Antagonist) Study to Evaluate Safety, Tolerability and Efficacy in Parkinson’s Disease Dementia (SYNAPSE): Phase 2a Study Results

H. Fernandez (Cleveland, OH, USA)

1:45pm-3:15pm: The Akt/mTOR/P70S6K/4EB-P1 signaling pathway is activated by metformin in a toxin-induced cellular model of Parkinson’s disease

P. Dharmasaroja, P. Chanthammachat (Bangkok, Thailand)

1:45pm-3:15pm: The anti-dyskinetic effect of the clinically-available 5-HT3 receptor antagonist granisetron in the 6-OHDA-lesioned rat model of Parkinson’s disease

C. Kwan, I. Frouni, D. Bedard, A. Hamadjida, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm: The BeyoND study: Design and baseline characteristics of a study evaluating the long-term safety of ND0612 for motor fluctuations in Parkinson’s disease

W. Poewe, F. Stocchi, A. Espay, T. Rachmilewitz Minei, S. Oren, R. Case, K. Kieburtz, C. Olanow (Innsbruck, Austria)

1:45pm-3:15pm: The combined effect of repetitive transcranial magnetic stimulation and treadmill training in people with Parkinson’s disease – A randomized controlled trial

C. Chung, M. Mak, M. AuYeung, Y. Chan, N. Cheung, V. Mok, M. Hallett (Hong Kong, Hong Kong)

1:45pm-3:15pm: The complementary relationship between zonisamide and istradefylline in treating patients with Parkinson’s disease

T. Kadowaki, M. Hamaguchi, H. Sakuramoto, T. Shiina, H. Fujita, K. Suzuki, K. Hirata (Mibu, Japan)

1:45pm-3:15pm: The course of Parkinson’s disease in patients with impaired carbohydrate metabolism

F. Akhmedova, B. Shagazatova, D. Artikova, F. Mirxaydarova (Tashkent, Uzbekistan)

1:45pm-3:15pm: The Effect of Conduction Exercise and Self-acupressure in Treatment of Parkinson’s Disease: A Pilot Study

M. Li, K.K. Chua, C.S. Yuen, Z.Y. Zhuang, W.H. Lau, H.Y. Chow (Hong Kong)

1:45pm-3:15pm: The Effect of Short Pulse Width Settings on Speech in Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s disease

V. Dayal, T. Grover, E. Tripoliti, P. Limousin, T. Foltynie (London, United Kingdom)

1:45pm-3:15pm: The effectiveness of boxing exercise in elderly patients including Parkinson’s disease patients

N. Kawashima, M. Isogai, M. Matsuhashi, M. Komachi, H. Ikebe, A. Kumon, K. Miyashita, A. Sato, K. Hasegawa (Fujisawa, Japan)

1:45pm-3:15pm: The effects of bright light therapy on depression, sleep and circadian rhythm in patients with Parkinson’s disease and a depressive disorder: Results of a double-blind randomized controlled trial

S. Rutten, C. Vriend, J. Smit, H. Berendse, E. van Someren, A. Hoogendoorn, J. Twisk, Y. vd Werf, O. vd Heuvel (Amsterdam, Netherlands)

1:45pm-3:15pm: The effects of STN-DBS on the Parkinson’s disease patients with different progressive rates

R. Qi, H. Yu, J. Li, X. Geng (Kunming, China)

1:45pm-3:15pm: The effects of treadmill training augmented by virtual reality on postural control and freezing of gait in Parkinson’s disease

E. Bekkers, A. Mirelman, S. Del Din, L. Avanzino, F. Nieuwhof, J. Hausdorff, A. Nieuwboer (Leuven, Belgium)

1:45pm-3:15pm: The efficacy of intensive inpatient rehabilitation treatment in Parkinson’s disease patients

J. Shiraishi, T. Okazaki, S. Saeki (Fukuoka, Japan)

1:45pm-3:15pm: The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

I. Frouni, D. Bedard, S. Belliveau, E. Bourgeois-Cayer, A. Hamadjida, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm: The Impact of Vocal Fold Augmentation with Injection Laryngoplasty on Voice Quality in Patients with Parkinson Disease

O. Klepitskaya, J. Barr, Y. Liu, S. Sillau, J. Litts, D. Fink, M. Shaffer, J. Newcombe, A. Klepitskaya, M. Clary (Aurora, CO, USA)

1:45pm-3:15pm: The Interface of advanced therapies as Parkinson’s disease progresses – case reports

C. Liang, S. Williams, L. Jones, C. Sue, P. Silberstein (St Leonards, Australia)

1:45pm-3:15pm: The NIC-PD-study –A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson‘s disease in Germany and N. America

W. Oertel, H. Müller, C. Schade-Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, M. Unger, K. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

1:45pm-3:15pm: The outcome of directional subthalamic deep brain stimulation in advanced Parkinson’s disease

M. Koivu, F. Scheperjans, J. Eerola-Rautio, J. Resendiz-Nieves, J. Marjamaa, R. Kivisaari, E. Pekkonen (Helsinki, Finland)

1:45pm-3:15pm: The possibility of medicamentous correction of the lower urinary tract dysfunction in patients with Parkinson’s disease

M. Tukhtamishev, T. Khodjimetov, F. Akhmedova (Tashkent, Uzbekistan)

1:45pm-3:15pm: The use of gliatilin in the complex treatment of vascular parkinsonism

S. Lukmonov, D. Tolibov (Tashkent, Uzbekistan)

1:45pm-3:15pm: Treatment of Levodopa Dose Failure with Subcutaneous Apomorphine Injection

S. Isaacson (Boca Raton, FL, USA)

1:45pm-3:15pm: Treatment with levodopa/carbidopa intestinal gel of advanced Parkinson’s disease patients: Bulgarian experience

E. Chorbadzhieva (Sofia, Bulgaria)

1:45pm-3:15pm: TreCap: Quantify and assess tremor in real-time with a new wearable device

R. Bremm, J. Goncalves, K. Koch, F. Hertel (Belvaux, Luxembourg)

1:45pm-3:15pm: Update on The Personalized Parkinson Project: Partnering with Patients to Understand Disease Progression Through a Multi-Dimensional Approach

B. Bloem, R. Kapur, T. v/d Zande, M. Faber, W. Marks, Jr (Nijmegen, Netherlands)

1:45pm-3:15pm: Use of safinamide: A clinical practice review of 2 year experience

C. Borrue-Fernandez (San Sebastian Reyes, Spain)

1:45pm-3:15pm: Variation in the L-dopa motor response in pathologically confirmed Parkinson’s disease

V. Pitz, N. Malek, K. Grosset, D. Grosset (Glasgow, United Kingdom)

1:45pm-3:15pm: VY-AADC01 gene therapy in Parkinson’s disease: Interim results of the on-going Phase 1b PD-1101 trial

P. Larson, K. Bankiewicz, A. Van Laar, R. Richardson, B. Ravina, A. Kells, B. Boot, A. Martin, M. Thompson, C. Christine (San Francisco, CA, USA)

1:45pm-3:15pm: Weight loss and nutritional status in Parkinson’s disease patients under levodopa/carbidopa intestinal gel infusion treatment

M. Fabbri, M. Zibetti, L. Beccaria, A. Romagnolo, E. Montanaro, J. Ferreira, L. Lopiano (Lisbon, Portugal)

1:45pm-3:15pm: Weight variation in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion

B. Fernández-Rodríguez, J. Dupouy, E. Harroch, MH. Fabre-Delcros, C. Barthélémy, P. Loubière, K. Barange, C. Brefel-Courbon, O. Rascol, F. Ory-Magne (Toulouse, France)

1:45pm-3:15pm: What makes a successful Phase 2 study: An evaluation of Parkinson’s neuroprotective trial design over the last 5 years

T. Dominey, S. Buff, G. Rafaloff, C. Carroll (Plymouth, United Kingdom)

1:45pm-3:15pm: Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture

J. Ferrario, A. Bernardi, P. Ballestero, M. Ferrario, M. Schenk, E. Avale, S. Guerrero, O. Gershanik (Buenos Aires, Argentina)

« View all sessions from the 2018 International Congress.